Cargando…
Encapsulated Cell Technology-Based Delivery of a Complement Inhibitor Reduces Choroidal Neovascularization in a Mouse Model
PURPOSE: Age-related macular degeneration (AMD) is a slowly progressing disease, and risk appears to be tied to an overactive complement system. We have previously demonstrated that mouse choroidal neovascularization (CNV) and smoke-induced ocular pathology can be reduced with an alternative pathway...
Autores principales: | Annamalai, Balasubramaniam, Parsons, Nathaniel, Belhaj, Marwa, Brandon, Carlene, Potts, Jay, Rohrer, Bärbel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Association for Research in Vision and Ophthalmology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846441/ https://www.ncbi.nlm.nih.gov/pubmed/29576927 http://dx.doi.org/10.1167/tvst.7.2.3 |
Ejemplares similares
-
The use of Matrigel combined with encapsulated cell technology to deliver a complement inhibitor in a mouse model of choroidal neovascularization
por: Annamalai, Balasubramaniam, et al.
Publicado: (2020) -
Delivery of CR2-fH Using AAV Vector Therapy as Treatment Strategy in the Mouse Model of Choroidal Neovascularization
por: Schnabolk, Gloriane, et al.
Publicado: (2017) -
Regulatable Complement Inhibition of the Alternative Pathway Mitigates Wet Age-Related Macular Degeneration Pathology in a Mouse Model
por: Parsons, Nathaniel B., et al.
Publicado: (2023) -
Subretinal Rather Than Intravitreal Adeno-Associated Virus–Mediated Delivery of a Complement Alternative Pathway Inhibitor Is Effective in a Mouse Model of RPE Damage
por: Annamalai, Balasubramaniam, et al.
Publicado: (2021) -
Dabigatran and Wet AMD, Results From Retinal Pigment Epithelial Cell Monolayers, the Mouse Model of Choroidal Neovascularization, and Patients From the Medicare Data Base
por: Akter, Tanjina, et al.
Publicado: (2022)